Molbio Diagnostics Ltd Q1 FY27 Results Analysis: Revenue Surges 309%, EBITDA Margin Turns Positive

Molbio Diagnostics Ltd's Q1 FY27 numbers came in strong. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Q1 FY27 revenue surged 309% YoY, flipping from loss to profit with EBITDA margin improving from -16.2% to 24.6%. The IPO was completed post-quarter, strengthening the balance sheet. However, 27% QoQ revenue decline reflects seasonality, and subsidiary losses dragged consolidated PAT.

Key Investment Insights

Key Positives

• Revenue grew 309% YoY to Rs.4,083.76 Million, from Rs.997.08 Million in Q1 FY26.
• Turned profitable from loss: PAT of Rs.527.44 Million vs loss of Rs.239.44 Million in Q1 FY26.
• EBITDA margin improved from -16.2% to 24.6% YoY, demonstrating operating leverage.
• Completed IPO raising Rs.2,000 Million fresh issue, listed on NSE and BSE.
• Raw material costs declined 45.7% QoQ despite revenue decline of 27.2%, indicating good inventory management.

Risk Factors

• Revenue declined 27.2% QoQ to Rs.4,083.76 Million, indicating seasonality in diagnostic device demand.
• Non-controlling interest recorded loss of Rs.60.03 Million, dragging consoliated PAT; subsidiaries (e.g., OptraSCAN) in investment phase.
• Finance costs nearly tripled YoY (+196.2%) to Rs.106.99 Million, reflecting acquisition-related debt.
• Purchase of traded goods spiked 578.5% QoQ despite revenue decline, potential channel inventory build.
• Tax dispute of Rs.208.71 Million under Section 133A with Rs.78.95 Million paid under protest.